Role of JAK inhibitors and immune cells in transplantation |
| |
| Institution: | 1. Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France;2. Institut de Transplantation Urologie Néphrologie, CHU Nantes, Nantes, France;3. Université de Nantes, Nantes Atlantique Universités, Cibles et Médicaments du Cancer et de l’Immunité IICiMed-AE1155, Institut de Recherche en Santé 2, Nantes, France;1. McDermott Center for Human Growth and Development and the Department of Internal Medicine, University of Texas Southwestern Medical Center. Dallas, TX;1. Department of Medicine, Center for Behavioral Cardiovascular Health, Columbia University, New York, NY;2. Department of Health Policy & Management, Mailman School of Public Health, Columbia University, New York, NY;3. Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL;1. Department of Pancreas and Kidney Transplantation, Scientific-Research Institute of Emergency Care named after N.V. Sklifosovsky, Moscow, Russia;2. Surgery Block for Organ Transplantation, Scientific-Research Institute of Emergency Care named after N.V. Sklifosovsky, Moscow, Russia;1. Norton Thoracic Institute, St. Joseph’s Hospital and Medical Center, Phoenix, AZ;2. Department of Pathology, St. Joseph’s Hospital and Medical Center, Phoenix, AZ;3. Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH |
| |
| Abstract: | Immunosuppressive challenge after transplantation has dual objectives, namely, to efficiently inhibit immune populations involved in acute, chronic, humoral or cellular transplant rejection while minimizing the effect on immune integrity toward pathogens. The current immunosuppressive strategies show limited efficacy and remain associated with strong side effects, and thus, it is essential to develop new strategies. The use of Janus kinase (JAK) inhibitors is one of the new strategies focusing on cytokine pathways. Specifically, the first-generation JAK inhibitors (JAKis) showed low specificity toward the four known JAK molecules and did not exhibit better effects than calcineurin inhibitors, which constitute the standard treatment posttransplantation. However, because the new generation of JAKis present higher specificity, we are gaining further insights on the response of cells to these inhibitions. This review focuses on the impact of JAKis on different immune cell subsets, focusing on their role in transplantation. |
| |
| Keywords: | Cytokine JAK inhibitor JAK Transplantation Immunosuppressive treatment |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
